- Home
- RMSG vs IGC Comparison
RMSG vs IGC Comparison
Compare RMSG & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMSG
- IGC
- Stock Information
- Founded
- RMSG 2022
- IGC 2005
- Country
- RMSG United States
- IGC United States
- Employees
- RMSG N/A
- IGC N/A
- Industry
- RMSG
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- RMSG
- IGC Health Care
- Exchange
- RMSG NYSE
- IGC Nasdaq
- Market Cap
- RMSG 21.9M
- IGC 20.2M
- IPO Year
- RMSG N/A
- IGC N/A
- Fundamental
- Price
- RMSG $2.28
- IGC $0.29
- Analyst Decision
- RMSG
- IGC Strong Buy
- Analyst Count
- RMSG 0
- IGC 2
- Target Price
- RMSG N/A
- IGC $3.88
- AVG Volume (30 Days)
- RMSG 12.8K
- IGC 196.9K
- Earning Date
- RMSG 05-25-2025
- IGC 06-23-2025
- Dividend Yield
- RMSG N/A
- IGC N/A
- EPS Growth
- RMSG N/A
- IGC N/A
- EPS
- RMSG N/A
- IGC N/A
- Revenue
- RMSG N/A
- IGC $1,236,000.00
- Revenue This Year
- RMSG N/A
- IGC N/A
- Revenue Next Year
- RMSG N/A
- IGC $16.45
- P/E Ratio
- RMSG N/A
- IGC N/A
- Revenue Growth
- RMSG N/A
- IGC 1.65
- 52 Week Low
- RMSG $1.38
- IGC $0.25
- 52 Week High
- RMSG $55.28
- IGC $0.62
- Technical
- Relative Strength Index (RSI)
- RMSG N/A
- IGC 46.51
- Support Level
- RMSG N/A
- IGC $0.28
- Resistance Level
- RMSG N/A
- IGC $0.32
- Average True Range (ATR)
- RMSG 0.00
- IGC 0.01
- MACD
- RMSG 0.00
- IGC -0.00
- Stochastic Oscillator
- RMSG 0.00
- IGC 26.50
About RMSG REAL MESSENGER CORP
Real Messenger Corp is a technology company built as a social platform focused on reinstating joy, fun, and a sense of community at every stage of the real estate journey. The company is engaged in revolutionizing real estate communication, connecting all stakeholders through chat app, enabling real-time messaging, documentation, and integration with other real-estate software in a safe and secure environment.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.